Major advancements in artificial intelligence (AI) have attracted billions of dollars in new investment, and the IPO market has taken notice. The percentage of US IPOs referencing AI in their prospectuses has climbed in each of the past six years, and leapt to...read more
The IPO market remained active this past week as four IPOs raised $2.3 billion, joined by two direct listings. SPAC activity kept steady with nine blank check IPOs. New filers continue to pour into the IPO pipeline, with 17 IPOs and 10 SPACs submitting initial...read more
Exscientia, which develops and licenses therapies designed with its AI drug discovery platform, raised $305 million by offering 13.9 million ADSs at $22, the high end of the range of $20 to $22. The company offered 0.8 million more ADSs than anticipated. It also...read more
Exscientia, which provides an AI-driven platform for drug design, discovery, and development, announced terms for its IPO on Monday. The Oxford, United Kingdom-based company plans to raise $275 million by offering 13.1 million ADSs at a price range of $20 to...read more
AI is the IPO market's next buzzword
Major advancements in artificial intelligence (AI) have attracted billions of dollars in new investment, and the IPO market has taken notice. The percentage of US IPOs referencing AI in their prospectuses has climbed in each of the past six years, and leapt to...read more
US IPO Weekly Recap: The IPO market can see clearly now in a 4 IPO, 2 direct listing week
The IPO market remained active this past week as four IPOs raised $2.3 billion, joined by two direct listings. SPAC activity kept steady with nine blank check IPOs. New filers continue to pour into the IPO pipeline, with 17 IPOs and 10 SPACs submitting initial...read more
Drug discovery platform Exscientia prices upsized US IPO at $22 high end
Exscientia, which develops and licenses therapies designed with its AI drug discovery platform, raised $305 million by offering 13.9 million ADSs at $22, the high end of the range of $20 to $22. The company offered 0.8 million more ADSs than anticipated. It also...read more
Drug discovery platform Exscientia sets terms for $275 million US IPO
Exscientia, which provides an AI-driven platform for drug design, discovery, and development, announced terms for its IPO on Monday. The Oxford, United Kingdom-based company plans to raise $275 million by offering 13.1 million ADSs at a price range of $20 to...read more